Dr. Reddy’s Laboratories Allots Equity Shares to Employees

Dr Reddy’s Laboratories ( (RDY) ) has issued an announcement.

On June 14, 2025, Dr. Reddy’s Laboratories announced the allotment of 57,885 equity shares to eligible employees as part of their stock options schemes. This move is part of the company’s ongoing efforts to incentivize and retain talent through share-based employee benefits, aligning employee interests with company growth. The allotment reflects the company’s commitment to employee engagement and its strategic focus on enhancing shareholder value.

The most recent analyst rating on (RDY) stock is a Buy with a $17.40 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.

Spark’s Take on RDY Stock

According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.

Dr Reddy’s Laboratories’ strong financial performance is the most significant factor, underscored by consistent revenue growth and profitability. Technical analysis supports a favorable stock trend, although valuation is fair with modest income potential. The absence of earnings call and corporate events data did not impact the overall score.

To see Spark’s full report on RDY stock, click here.

More about Dr Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited is a pharmaceutical company based in Hyderabad, India. It is engaged in the manufacturing and marketing of a wide range of pharmaceuticals in India and overseas. The company is listed on multiple stock exchanges including BSE, NSE, and NYSE, and focuses on providing affordable and innovative medicines for healthier lives.

Average Trading Volume: 2,150,636

Technical Sentiment Signal: Strong Buy

Current Market Cap: $13B

Find detailed analytics on RDY stock on TipRanks’ Stock Analysis page.